Am J Blood Res 2012;2(1):9-17
Review Article
Role of high-dose melphalan and autologous peripheral blood stem cell
transplantation in AL amyloidosis
Vaishali Sanchorawala
Amyloid Treatment and Research Program and Stem Cell Transplantation Program of Section of Hematology and Oncology,
Boston Medical Center, Boston, MA 02118, USA.
Received December 18, 2011; accepted December, 2011; Epub December, 2011; published January 15, 2012
Abstract: AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma
cell dyscrasia. The disease is often difficult to recognize because of its broad range of manifestations and, what are often,
vague symptoms. Recent diagnostic and prognostic advances include the serum free light chain assay, cardiac magnetic
resonance imaging, and serologic cardiac biomarkers. Treatment strategies that have evolved during the past decade are
prolonging survival and preserving organ function in patients with this disease. This review outlines the role of high dose
melphalan and stem cell transplantation in the treatment of AL amyloidosis. (AJBR11120002).
Keywords: AL amyloidosis, stem cell transplantation, melphalan
Full Text PDF
Address all correspondence to:
Dr. Vaishali Sanchorawala
Amyloid Treatment and Research Program
Stem Cell Transplantation Program
Section of Hematology and Oncology
Boston Medical Center, Boston, MA 02118, USA.
E-mail: vaishali.sanchorawala@bmc.org
Review Article
Role of high-dose melphalan and autologous peripheral blood stem cell
transplantation in AL amyloidosis
Vaishali Sanchorawala
Amyloid Treatment and Research Program and Stem Cell Transplantation Program of Section of Hematology and Oncology,
Boston Medical Center, Boston, MA 02118, USA.
Received December 18, 2011; accepted December, 2011; Epub December, 2011; published January 15, 2012
Abstract: AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma
cell dyscrasia. The disease is often difficult to recognize because of its broad range of manifestations and, what are often,
vague symptoms. Recent diagnostic and prognostic advances include the serum free light chain assay, cardiac magnetic
resonance imaging, and serologic cardiac biomarkers. Treatment strategies that have evolved during the past decade are
prolonging survival and preserving organ function in patients with this disease. This review outlines the role of high dose
melphalan and stem cell transplantation in the treatment of AL amyloidosis. (AJBR11120002).
Keywords: AL amyloidosis, stem cell transplantation, melphalan
Full Text PDF
Address all correspondence to:
Dr. Vaishali Sanchorawala
Amyloid Treatment and Research Program
Stem Cell Transplantation Program
Section of Hematology and Oncology
Boston Medical Center, Boston, MA 02118, USA.
E-mail: vaishali.sanchorawala@bmc.org
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |